CN117015380A - 多环IRAK和flt3抑制化合物以及其用途 - Google Patents

多环IRAK和flt3抑制化合物以及其用途 Download PDF

Info

Publication number
CN117015380A
CN117015380A CN202180093913.0A CN202180093913A CN117015380A CN 117015380 A CN117015380 A CN 117015380A CN 202180093913 A CN202180093913 A CN 202180093913A CN 117015380 A CN117015380 A CN 117015380A
Authority
CN
China
Prior art keywords
inhibitors
compound
alkyl
flt3
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180093913.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·B·霍伊特
C·J·托马斯
D·T·斯塔奇诺夫斯基
J·S·罗森鲍姆
G·格拉西亚马尔多纳多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kulom Treatment Co
Cincinnati Childrens Hospital Medical Center
US Department of Health and Human Services
Original Assignee
Kulom Treatment Co
Cincinnati Childrens Hospital Medical Center
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kulom Treatment Co, Cincinnati Childrens Hospital Medical Center, US Department of Health and Human Services filed Critical Kulom Treatment Co
Publication of CN117015380A publication Critical patent/CN117015380A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180093913.0A 2020-12-23 2021-12-23 多环IRAK和flt3抑制化合物以及其用途 Pending CN117015380A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063129895P 2020-12-23 2020-12-23
US63/129895 2020-12-23
PCT/US2021/065037 WO2022140647A1 (en) 2020-12-23 2021-12-23 Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN117015380A true CN117015380A (zh) 2023-11-07

Family

ID=82158501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180093913.0A Pending CN117015380A (zh) 2020-12-23 2021-12-23 多环IRAK和flt3抑制化合物以及其用途

Country Status (9)

Country Link
US (1) US12612410B2 (https=)
EP (1) EP4267142A4 (https=)
JP (1) JP2024501658A (https=)
CN (1) CN117015380A (https=)
AU (1) AU2021410783A1 (https=)
CA (1) CA3201841A1 (https=)
IL (1) IL303887A (https=)
MX (1) MX2023006938A (https=)
WO (1) WO2022140647A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250431A2 (en) * 2022-06-22 2023-12-28 Children's Hospital Medical Center Multi-cyclic irak and flt3 inhibiting compounds and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083492A1 (en) * 2009-04-16 2012-04-05 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyrazines for use as kinase inhibitors
WO2018038988A2 (en) * 2016-08-17 2018-03-01 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20180071303A1 (en) * 2016-09-14 2018-03-15 Gilead Sciences, Inc. Syk inhibitors
WO2019002606A1 (en) * 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS
US20200199123A1 (en) * 2016-08-17 2020-06-25 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20200270242A1 (en) * 2016-08-17 2020-08-27 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507032A (ja) * 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
US10138248B2 (en) * 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083492A1 (en) * 2009-04-16 2012-04-05 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyrazines for use as kinase inhibitors
CN102428087A (zh) * 2009-04-16 2012-04-25 西班牙国家癌症研究中心 用作激酶抑制剂的咪唑并吡嗪类化合物
WO2018038988A2 (en) * 2016-08-17 2018-03-01 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20200199123A1 (en) * 2016-08-17 2020-06-25 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20200270242A1 (en) * 2016-08-17 2020-08-27 Children's Hospital Medical Center Compounds, compositions, methods for treating diseases, and methods for preparing compounds
US20180071303A1 (en) * 2016-09-14 2018-03-15 Gilead Sciences, Inc. Syk inhibitors
WO2019002606A1 (en) * 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
巴德年主编: "《基础医学卷 分子药理学》", vol. 1, 31 May 1999, 黑龙江科学技术出版社, pages: 299 - 302 *

Also Published As

Publication number Publication date
AU2021410783A9 (en) 2024-10-17
IL303887A (en) 2023-08-01
MX2023006938A (es) 2023-10-13
US20240294530A1 (en) 2024-09-05
US12612410B2 (en) 2026-04-28
AU2021410783A1 (en) 2023-08-10
EP4267142A1 (en) 2023-11-01
CA3201841A1 (en) 2022-06-30
WO2022140647A1 (en) 2022-06-30
JP2024501658A (ja) 2024-01-15
EP4267142A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
RU2602233C2 (ru) Замещенные бензопиразиновые производные в качестве ингибиторов fgfr-киназ для лечения раковых заболеваний
US12534469B2 (en) Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof
WO2025101776A1 (en) Heterocycles and uses thereof
JP2023538242A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
US20250154144A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN117015380A (zh) 多环IRAK和flt3抑制化合物以及其用途
US20250368648A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023150601A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
CN118613480A (zh) 多环irak和flt3抑制化合物以及其用途
HK40101779A (zh) 多环irak和flt3抑制化合物以及其用途
JP2026506363A (ja) 多環式ｉｒａｋ及びｆｌｔ３阻害化合物並びにその使用
WO2024076614A2 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2023250431A9 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2025137567A1 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
WO2025059429A1 (en) Modulators of bcl6 for use in a method of treating a cancer or an autoimmune disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination